The 786-0 renal cancer cell-derived exosomes promote angiogenesis by downregulating the expression of hepatocyte cell adhesion molecule

Introduction

Renal cancer is a urinary tumor that affects individuals worldwide, accounting for ~3% of all systemic malignancies (1). Furthermore, it is one of the most common forms of cancer in China. Exosomes are classically defined as membranous vesicles with a diameter of 30–100 nm and cup-shaped morphology that are secreted by a broad array of cells during physiological and pathological conditions (2). These organelles exert versatile functions due to significant variations in their contents from the originating cell, including a large array of proteins, RNA, mRNA and lipids (2,3). Previous studies reported that extracellular organelles are important mediators of intercellular community (4–9). Tumor cell-derived exosomes are associated with numerous events in cancer pathogenesis and development, including tumor angiogenesis (10).

Beginning at the early phases of the neoplastic process, tumor cells begin to manipulate the host environment to favor their survival and growth (11). Vessels are markedly associated with the pathogenesis and development of tumors and it has been demonstrated that cells at the preneoplastic stage must acquire angiogenic capacity to become malignant cells. Without blood vessels, tumors cannot grow and form metastases (12–14). Vascular endothelial growth factor (VEGF) is the most important factor for the induction and regulation of proliferation of vascular endothelial cells as well as angiogenesis in physiological and pathological conditions. High expression of VEGF has been detected in kidney cancer tissue and serum (3,15). Thus, VEGF is an important target for studies in renal cancer immunity therapy. Hepatocyte cell adhesion molecule (hepaCAM) was previously identified as a novel member of the immunoglobulin super family and was undetectable or expressed at low levels in a number of cancer cells and tissues, including renal cancer (16–18). Therefore, hepaCAM has been hypothesized to be a candidate tumor suppressor gene. In our previous study, hepaCAM was undetectable in transitional cell carcinoma of bladder cell lines T24 and BIU-87, and low hepaCAM levels were found to correlate with increased VEGF levels (19), indicating that hepaCAM is important in suppression of tumor angiogenesis.

Thus, the aim of the current study was to determine whether renal cancer-derived exosomes upregulate VEGF expression via the downregulation of hepaCAM expression, leading to the promotion of angiogenesis.

Materials and methods

Cell lines and culture

Human renal cancer cell line, 786-0 and human umbilical vein endothelial cell (HUVEC) line, hy-926, were gifts from the College of Laboratory Medicine (Chongqing Medical University). The cell lines were maintained in RPMI-1640 medium (Gibco-BRL, Shanghai, China) supplemented with 10% fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT, USA) in a 5% CO2 humid incubator at 37°C. Experiments were performed at the cell logarithmic growth phase.

Adenovirus transfection

When cell confluence reached 90%, serum-free medium was exchanged and the adenovirus solution (recombinant adenovirus AdI-EGFP and AdI-hepaCAM) was added to the flask. Complete medum (RPMI-1640 medium supplemented with 10% fetal bovine serum) was added following 1.5 h and protein from each group was extracted following 72-h incubation.

Extraction and identification of exosomes

Supernatants of cultured 786-0 cells were collected and subsequently centrifuged at 4°C at 300 × g for 10 min, 800 × g for 30 min and 10,000 × g for 30 min to deposit cells and debris. Supernatants were concentrated by ultrafiltration using a 100 kDa MWCO Centriplus centrifugal ultrafiltration tube (Millipore, Billerica, MA, USA) at 1,000 × g for 30 min. Remaining supernatants were concentrated and subjected to ultracentrifugation in a centrifugal ultrafiltration tube containing 30% sucrose in heavy water (Tenglong Weibo Technology, Qingdao, China) at 100,000 × g for 1 h at 4°C. The sucrose solution was collected and diluted with phosphate-buffered saline, followed by concentration using an additional 100 kDa MWCO Centriplus centrifugal ultrafiltration tube at 1,000 × g for 30 min. Finally, the remaining exosome-containing solution was collected, filtered through a 0.22 μm filter, aliquoted and stored at −80°C. Exosomes were characterized by transmission electron microscopy.

Exosome suspension (20 μl) was dropped on the copper-net and the sample was dried using filter paper 1 min later. Subsequently, the sample was negatively stained by 2% Salkowski’s solution for 1 min and dried using incandescent lights for 10 min. The sample was then observed and images were captured using transmission electron microscopy.

Matrigel tubular assay

Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) was thawed at 4°C, applied to a 24-well plate and incubated at 37°C for 12 h to allow solidification. Then, hy926 cells were seeded onto the matrigel at 1×105 cells/well with or without renal cell-derived exosomes. Following incubaton for 72 h, tubular formation of the cells was observed and images were captured. The assay was performed in 5 wells/group.

Reverse transcription-polymerase chain reaction (RT-PCR) analysis

Total RNA was isolated from cells using TRIzol (Takara Bio, Inc., Shiga, Japan) and semi-quantitative RT-PCR was performed using the Two-step RT-PCR kit (Takara Bio, Inc.) following the manufacturer’s instructions. Primers were designed using Primer Premier 5.0 (Premier Biosoft, Palo Alto, CA, USA) and gene primer specificity was confirmed by BLAST search using the GeneBank database. The primers used were: hepaCAM, forward: 5′-TAC TGT AGA TGT GCC CAT TTC G-3′ and reverse: 5′-CTT CTG GTT TCA GGC GGT C-3′; VEGF, forward: 5′-GTC CAA CTT CTG GGC TGT TCT-3′ and reverse: 5′-ACC ACT TCG TGA TGA TTC TGC-3′; and β-actin (loading control), forward: 5′-TGA CGT GGA CAT CCG CAA AG-3′ and reverse: 5′-CTG GAA GGT GGA CAG CGA GG-3′. Amplified hepaCAM, VEGF and β-actin fragments were 461, 497 and 205-bp in length, respectively. Total RNA was reverse transcribed and RT-PCR was performed using 1 μl cDNA and primers for relevant genes under the following optimized conditions: predenaturation, 95°C for 5 min; 35 cycles of denaturation at 95°C for 30 sec, annealing at 56°C, 59°C or 56°C for 30 sec and extension at 72°C for 1 min; and final extension, 72°C for 5 min. Products were analyzed by 1.5% gel electrophoresis using a Bio-Rad imaging plate (Bio-Rad, Hercules, CA, USA).

Western blot analysis

Cells were solubilized in lysis buffer (Beyotime Institute of Biotechnology, Jiangsu, China) containing 1 μl phenylmethanesulfonyl fluoride and then centrifuged at 4°C at 13200 × g for 5 min to obtain the supernatant. The concentration was determined by BCA method. Proteins were separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and the protein bands were transferred to polyvinylidene fluoride membranes (Amersham Pharmacia Biotech, Amersham, UK). Membranes were blocked in 5% skimmed milk for 2 h and incubated with anti-hepaCAM (Wuhan Sanying Biotechnology Inc., Wuhan, China), anti-VEGF and anti-β-actin (Wuhan Boster Biological Technology, Ltd., Wuhan, China) antibodies overnight at 4°C. Following three 10 min washes with TBST, membranes were incubated with HRP-conjugated secondary antibody for 1.5 h. Membranes were washed again (three 10 min washes with TBST) and the immunoreactive bands were detected using an enhanced chemoluminescence kit (Beyotime Institute of Biotechnology, China) in the dark. β-actin was used as an internal control. The intensity of the protein bands was quantified using Quantity-One software (Bio-Rad).

Statistical analysis

Statistical differences between the groups were analyzed using the Kruskal-Wallis test. Data are presented as mean ± SD. P<0.05 was considered to indicate a statistically significant difference.

Results

Morphological identification of exosomes

TEM analysis of exosomes indicated that typical characteristics of a cup-shaped or saucer-like structure with a size ranging from 30–100 nm in diameter (Fig. 1).

Figure 1 786-0 cell-derived exosomes visualized under electron microscopy (original magnification, ×50,000).

In vitro tube formation of exosome-treated HUVECs is markedly increased by treatment with exosomes

HUVECs formed tubular structures in the matrigel and the effect was examined 72 h following treatment. Compared with the control group, cells treated with 50 or 150 μg/ml exosomes exhibited a marked increase in the formation of tubular structures (both P<0.01; Fig. 2).

Figure 2 Tube formation of exosome-treated HUVECs was markedly increased in vitro. Compared with the control, groups treated with 50 or 150 μg/ml exosomes exhibited increased formation of tubular structures (magnification, ×100). HUVECs, human umbilical vein endothelial cells.

Re-expression of hepaCAM in 786-0 cells downregulates VEGF protein expression

hepaCAM expression was not detected in 786-0 cells and high VEGF expression was observed. Following transfection with AdI-hepaCAM, cells revealed increasing hepaCAM expression and decreasing VEGF expression compared with the AdI-EGFP group (both P<0.01; Fig. 3).

Figure 3 Re-expression of hepaCAM in 786-0 cells downregulated VEGF protein expression. hepaCAM gene was successfully transfected into 786-0 cells using recombinant adenovirus vehicles and VEGF expression was significantly decreased under hepaCAM re-expression. hepaCAM, hepatocyte cell adhesion molecule; VEGF, vascular endothelial growth factor.

hepaCAM and VEGF expression in HUVECs following treatment with exosomes

HUVECs expressed high levels of hepaCAM mRNA and a low expression of VEGF mRNA. Following treatment with renal cancer cell-derived exosomes, VEGF mRNA expression was found to be markedly decreased compared with the control group (50 and 150 μg/ml, both P<0.01; Fig. 4). Expression of hepaCAM mRNA was not found to be statistically significant compared with the control (50 and 150 μg/ml, both P<0.01; Fig. 5). Western blot analysis revealed that, compared with the control group, VEGF protein expression was markedly increased (50 and 150 μg/ml, both P<0.01) and hepaCAM protein expression was significantly decreased (50 and 150 μg/ml, both P<0.01). Levels of VEGF were found to inversely correlate with that of hepaCAM (Fig. 6).

Figure 4 VEGF mRNA expression following exosome treatment. Amplified VEGF and β-actin fragments were 497 and 205-bp in length, respectively. RT-PCR revealed that 150 μg/ml exosome treatment significantly increased VEGF expression. VEGF, vascular endothelial growth factor; RT-PCR, reverse transcription-polymerase chain reaction.

Figure 5 hepaCAM mRNA expression following exosome treatment. Amplified hepaCAM and β-actin fragments were 461 and 205-bp in length, respectively. RT-PCR demonstrated that exosome treatment had no effect on hepaCAM mRNA expression. hepaCAM, hepatocyte cell adhesion molecule; RT-PCR, reverse transcription-polymerase chain reaction.

Figure 6 hepaCAM and VEGF protein expression following 50 or 150 μg/ml exosome treatment. Groups revealed a reduced expression of hepaCAM and an increased expression of VEGF compared with control. hepaCAM, hepatocyte cell adhesion molecule; VEGF, vascular endothelial growth factor.

Discussion

Extensive studies on tumor cell-derived exosomes and their roles in intercellular communication in the tumor microenvironment have been performed (6,8,9,20–24). The tumor cell-derived exosome is known to manipulate the surrounding microenvironment to promote angiogenesis, invasion and metastasis, as well as escape immune surveillance (10). In the present study, exosomes secreted from the human renal cancer cell line, 786-0, were found to facilitate tubular formation via regulation of hepaCAM and VEGF expression of HUVECs.

Consistent with a number of previous studies (10,25–27), 786-0 cell-derived exosomes were observed to increase the formation of tubular stuctures in HUVECs compared with the control group. However, the underlying molecular mechanism of this effect remains unclear. Al-Nedawi et al revealed that exosomes transfer the oncogenic form of EGFR, EGFRvIII, from glioblastoma multiforme cells to endothelial cells (24), resulting in EGFRvIII-driven endothelial expression of autocrine VEGF. In the present study, expression of VEGF, an important factor in angiogenesis in physiological and pathological conditions, was upregulated in HUVECs at the mRNA and protein levels following treatment with cancer cell-derived exosomes, while hepaCAM protein levels decreased. In addition, re-expression of hepaCAM markedly reduced the expression of VEGF in 786-0 cells, which was consistent with our previous study (19). Induction of angiogenesis by VEGF has been found to be facilitated by the downregulation of expression (28) or decreasing stability of p53 (29) and is inhibited when p53 protein is upregulated (30). Re-expression of hepaCAM elevates p53 protein levels, while the knockdown of endogenous p53 expression via small-interfering RNA alleviates the proliferation inhibition of hepaCAM (17). In the current study, decreased hepaCAM partly induced increased levels of VEGF in HUVECs and the p53 signaling pathway was hypothesized to be be involved in this process.

In addition, no significant change in hepaCAM mRNA expression was identified and the lower protein level may be associated with post-transcriptional regulation. The specific mechanism by which hepaCAM protein is reduced and the associated signaling pathway requires further analysis. In a previous study, Zhang et al analyzed human breast carcinoma MCF7 cells, identifying a cleaved form of hepaCAM associated with the proteasome, calpain-1 and cathepsin B (18). Tumor cell-generated exosomes may directly modify adhesion molecules following transfer of these enzymes from parent to recipient cells. By contrast, specific immunoglobulin superfamily adhesion molecules, including ICAM-1, from activated endothelial cells are shed in soluble form, which may promote angiogenesis (31). Exosomes may also affect hepaCAM expression by activating the endothelial cells and shedding them from the membrane. In addition, the signaling pathways associated with exosome regulation of hepaCAM and VEGF remain unknown and require additional analysis.

In the present study, renal cancer 786-0 cell-derived exosomes significantly promoted angiogenesis via upregulation of VEGF expression in HUVECs, which may be induced by the downregulation of hepaCAM.

Acknowledgements

The authors would like to thank Dr Shali Shen for the kind support throughout the study and Professor Weixue Tang for providing technical guidance.

References